Investigations in the molecular events of transitional cell carcinoma of the bladder

American Journal of Biochemistry and Biotechnology

Volumn 4, Issue 4, 2008, Pages 408-415

  Kadhim, H S ^a   Abdulamir, A S ^a   Hafidh, R R ^a   Abubaker, F ^a   Abbas, K A ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

bcl 2; c myc; Immunohistochemistry; Ki 67; p53; Transitional cell carcinoma of the bladder

Indexed keywords

BCL-2; C-MYC; IMMUNOHISTOCHEMISTRY; KI-67; P53; TRANSITIONAL CELL CARCINOMA OF THE BLADDER;

CELL MEMBRANES; MUSCLE; ONCOGENIC VIRUSES; PROTEINS;

TUMORS;

CELL CYCLE PROTEIN; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; DRUG TARGETING; FEMALE; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR INTERACTION; MUSCLE CANCER; PATHOGENESIS; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; RELIABILITY; TRANSITIONAL CELL CARCINOMA;

EID: 68249128771     PISSN: 15533468     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajbbsp.2008.408.415     Document Type: Article

References (29)

1. Daniel, L., 2008. TNM staging: The commo nc language for cancer care. Am. Joint Committee Cancer, 28 Jul. 2008; http://www.cancerstaging.org/mission/ whatis.html
2. Shirai, T., 1993. Etiology of bladder cancer. Semin.Urol., 3: 113-116. http://www.ncbi.nlm.nih.gov/pubmed/8210833?dopt=Citation
3. Carroll, P.R., 1995. Urothelial Carcinoma: Cancers of the Bladder Ureter and Renal Pelvis. In: General Urology, Tanagho, E.A. and J.W. McAninch (Eds.). Prentice-Hall International Inc., USA., pp: 353-372.
4. Sandberg, A.A. and C.S. Berger, 1994. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J. Urol., 151: 545-560. http://www.ncbi.nlm.nih.gov/pubmed/7905930?dopt=Citation
5. Del Senno, L., I. Maestri, R. Piva, S. Hanau, A. Reggiani, A. Romano and G. Russo, 1989. Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J. Urol., 142: 146-149. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=2733094 (Pubitemid 19184027)
6. Williams, S.G., M. Buscarini and J.P. Stein, 2001. Molecular markers for diagnosis, staging and prognosis of bladder cancer. Oncology, 15: 1461-1484. http://www.cancernetwork.com/bladder-cancer/article/10165/99748
7. Zamamiri, F.A. and G.P. Zambetti, 2004. p53 Tumor Suppressor Genes. In: Cell Cycle and Growth Control, Biomolecular Regulation and Cancer, Stein, G.S. and A.B. Pardee (Eds.). John Wiley and Sons, Inc., Hoboken, New Jersey.pp: 365-371.
8. Bellamy, C.O., R. Malcomson and A. Wyllie, 1997. The Role of p53 in Apoptosis and Cancer. In: Apoptosis and Cancer, Martin, S.J., (Ed.). Karger Landes Systems, Basel, Switzerland, pp: 114-140.
9. Hayat, M.A., 2002. Microscopy, Immunohistochemistry and Antigen Retrieval Methods for Light and Electron Microscopy. 1st Edn., Kluwer Academic/Plenum Publishers, New York, ISBN: 0306467704, pp: 360-366.
10. Cho, H.J., J.K. Kim, K.D. Kim, H.K. Yoon, M.Y. Cho, Y.P. Park, J.H. Jeon, E.S. Lee, S.S. Byun, H.M. Lim, E.Y. Song, J.S. Lim, D.Y. Yoon, H.G. Lee and Y.K. Choe, 2006. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett., 237: 56-66. DOI: S0304-3835(05)00539-542
11. Reed, J.C., 1997. Bcl-2 Family Proteins: Role in Dysregulation of Apoptosis and Chemoresistance in Cancer. In: Apoptosis and Cancer, Martin, S.J. (Ed.). Karger Landes Systems, Basel, Switzerland. pp: 64-97.
12. Lindboe, C.F. and S.H. Torp, 2002. Comparison of Ki-67 equivalent antibodies. J. Clin. Pathol., 55: 467-471. http://www.pubmedcentral.nih.gov/ articlerender.fcgi?tool=pubmed&pubmedid=12037032
13. Kraggerud, S.M., K.D. Jacobsen and A. Berner, 1997. A comparison of different modes of the detection of p53 protein accumulation, a study of bladder cancer. Pathol. Res. Pract., 193: 471-478. http://www.ncbi.nlm.nih.gov/pubmed/ 9342752 or http://journals.indexcopernicus.com/abstracted.php?level=5&icid= 611450
14. Ong, F., L.M. Moonen and M.P. Gallee, 2001. Prognostic factors in TCC of the bladder: an emerging role for bcl-2 and p53. Radiother. Oncol., 61: 169-175. DOI: 10.1016/S0167-8140(01)00421-2
15. Pfister, C., L. Moore, P. Allard, H. Larue and Y. Fradet, 1999. Predictive value of cell cycle markers p53, MDM 2, p21 and Ki-67 in superficial bladder tumor recurrence. Clin. Cancer Res., 5: 4079-4084. http://clincancerres. aacrjournals.org/cgi/content/full/5/12/4079.
16. Pich, A., M. Margaria, L. Chiusa, P. Bortolin and G. Palestro, 2003. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm. Oncol. Rep., 10: 1329-1335. http://cat.inist.fr/?aModele=afficheN&cpsidt=14941760
17. Cordon-Cardo, C., 1995. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol., 147: 545-560. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1870966
18. Atug, F., L. Turkeri, M. Ozyurek and A. Akdas, 1998. bcl-2 and p53 overexpression as associated risk factors in TCC of the bladder. Int. Urol. Nephrol., 30: 455-461.DOI: 10.1007/BF02550226
19. Nakopoulou, L., C. Vourlakou and A. Zervas, 1998. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum. Pathol., 29: 146-154. http://cat.inist.fr/?aModele=afficheN&cpsidt=2184118
20. Mitra, A.P., M. Birkhahn and R.J. Cote, 2007. p53 and retinoblastoma pathways in bladder cancer. World J. Urol., 25: 563-571. DOI: 10.1007/s00345-007-0197-0
21. Black, P.C. and C.P. Dinney, 2007. Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastas. Rev., 26: 623-634. DOI: 10.1007/s10555-007-9084-9
22. Shiina, H., M. Igawa and S. Urakami, 1996. Immunohistochemical analysis of bcl-2 expression in TCC of the bladder. J. Clin. Pathol., 49: 395-399. DOI: 10.1136/jcp.49.5.395
23. Maluf, F.C., C. Cordon-Cardo, D.A. Verbel, J.M. Satagopan, M.G. Boyle, H. Herr and D.F. Bajorin, 2006. Assessing interactions between mdm-2, p53 and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by locoregional surgical treatment. Ann. Oncol., 17: 1677-1686. DOI: 10.1093/annonc/mdl289
24. Schmitz-Drager, B.J., W.A. Schulz, B. Jurgens, C.D. Gerharz, C.R. van Roeyen and H. Bultel, 1997. c-myc in bladder cancer, clinical findings and analysis of mechanism. Urol. Res., 25: S45-S49. DOI: 10.1007/BF00942047
25. Lipponen P.K. 1995. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J. Pathol., 175: 203-210. 10.1002/path.1711750208
26. Momota, H., A.H. Shih, M.A. Edgar and E.C. Holland, 2008. c-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene, 27: 4392-4401. DOI: onc200881 [pii]
27. Papaggeli, P.C., A.C. Kortsaris and P.T. Matsouka, 2003. Aberrant methylation of c-myc and c-fos protooncogenes and p53 tumor suppressor gene in myelodysplastic syndromes and acute nonlymphocytic leukemia. J. Balkan Union Oncol., 8: 341-350. http://www.ncbi.nlm.nih.gov/pubmed/17472275.
28. Masliukova, E.A., K.M. Pozharisskii, M.I. Karelin, V. Startsev and V.P. Ten, 2006. Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer. Vopr. Onkol., 52: 643-648. http://www.ncbi.nlm.nih.gov/pubmed/17338241.
29. Tsuji, M., K. Kojima and Y. Murakami, 1997. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: Immunohistochemical analysis of radical cystectomy specimens. Br. J. Urol., 79: 367-372. DOI: 10.1046/j.1464-410X.1997.02710.x